Clarity Pharmaceuticals Ltd (ASX:CU6) Insider Robert Thomas Purchases 8,333 Shares

Clarity Pharmaceuticals Ltd (ASX:CU6) insider Robert Thomas purchased 8,333 shares of Clarity Pharmaceuticals stock in a transaction dated Monday, May 20th. The shares were bought at an average price of A$4.29 ($2.86) per share, with a total value of A$35,706.91 ($23,804.60).

Robert Thomas also recently made the following trade(s):

• On Monday, April 29th, Robert Thomas 16,667 shares of Clarity Pharmaceuticals stock.

Clarity Pharmaceuticals Stock Performance

About Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2.